Randomized, Placebo-Controlled Trial to Assess the Safety and Immunogenicity of an Adenovirus type 35-Based Circumsporozoite Malaria Vaccine in Healthy Adults
12/2013
Journal Article
Authors:
Creech, C.B.;
Dekker, C.L.;
Ho, D.;
Phillips, S.;
Mackey, S.;
Murray-Krezan, C.;
Pau, G.;
Hendriks, J.;
Brown, V.;
Dally, L.G.;
Versteege, I.;
Edwards, K.M.
Secondary:
Hum Vaccin Immunother
Volume:
9
Pagination:
2548-2557
URL:
http://www.ncbi.nlm.nih.gov/pubmed/23955431
Keywords:
adenovirus; circumsporozoite; malaria; vaccine
Abstract:
Malaria results in over 650,000 deaths each year; thus, there is an urgent need for an effective vaccine. Pre-clinical studies and recently reported human trials suggest that pre-erythrocytic stage vaccines can provide protection against infection. A Phase 1, randomized, placebo-controlled, dose-escalation study was conducted with a vaccine composed of a replication-deficient adenovirus-35 backbone with P. falciparum circumsporozoite (CS) surface antigen (Ad35.CS.01). Healthy adult subjects received three doses of 10 (8), 10 (9), 10 (10), or 10 (11) vp/mL Ad35.CS.01 vaccine or saline placebo intramuscularly at 0, 1, and 6-mo intervals. Adverse events were assessed and anti-CS antibody responses were determined by ELISA. Seventy-two individuals were enrolled, with age, gender, and ethnicity similar across each study arm. While the vaccine was generally well tolerated, adverse events were more frequent in the highest dose groups (10 (10) and 10 (11) vp/mL). More robust humoral responses were also noted at the highest doses, with 73% developing a positive ELISA response after the three dose series of 10 (11) vp/mL. The Ad35.CS.01 vaccine was most immunogenic at the highest dosages (10 (10) and 10 (11) vp/mL). Reactogenicity findings were more common after the 10 (11) vp/mL dose, although most were mild or moderate in nature and resolved without therapy
